877 related articles for article (PubMed ID: 27777774)
1. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
[TBL] [Abstract][Full Text] [Related]
2. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
3. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
4. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
[TBL] [Abstract][Full Text] [Related]
7. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
[TBL] [Abstract][Full Text] [Related]
8. Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
Tang Y; Nan N; Gui C; Zhou X; Jiang W; Zhou X
Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):988-997. PubMed ID: 35672907
[TBL] [Abstract][Full Text] [Related]
9. The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.
Cui C; Yu B; Jiang Q; Li X; Shi K; Yang Z
Clin Exp Pharmacol Physiol; 2019 Jan; 46(1):3-10. PubMed ID: 30161295
[TBL] [Abstract][Full Text] [Related]
10. Induction of B7-H1 receptor by bacterial cells fractions of Porphyromonas gingivalis on human oral epithelial cells: B7-H1 induction by Porphyromonas gingivalis fractions.
Groeger S; Jarzina F; Mamat U; Meyle J
Immunobiology; 2017 Feb; 222(2):137-147. PubMed ID: 28164807
[TBL] [Abstract][Full Text] [Related]
11. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
12. CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ.
Wang H; Yan Z; Hao J; Yang B; Wang J; Yi L; Wang X; Li S; Zhang H; Zhang S
Thorac Cancer; 2019 Dec; 10(12):2225-2235. PubMed ID: 31625289
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
14. Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.
Jomrich G; Kollmann D; Ramazanova D; Ristl R; Grose RP; Ilhan-Mutlu A; Preusser M; Fassnacht C; Tsai YC; Guenova E; Schoppmann SF
Eur J Surg Oncol; 2022 Feb; 48(2):383-390. PubMed ID: 34404561
[TBL] [Abstract][Full Text] [Related]
15. Flow Cytometry Analysis of Surface PD-L1 Expression Induced by IFNγ and Romidepsin in Ovarian Cancer Cells.
Padmanabhan S; Zou Y; Vancurova I
Methods Mol Biol; 2020; 2108():221-228. PubMed ID: 31939184
[TBL] [Abstract][Full Text] [Related]
16. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.
Derks S; Nason KS; Liao X; Stachler MD; Liu KX; Liu JB; Sicinska E; Goldberg MS; Freeman GJ; Rodig SJ; Davison JM; Bass AJ
Cancer Immunol Res; 2015 Oct; 3(10):1123-1129. PubMed ID: 26081225
[TBL] [Abstract][Full Text] [Related]
17. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
[TBL] [Abstract][Full Text] [Related]
18. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.
Bigelow E; Bever KM; Xu H; Yager A; Wu A; Taube J; Chen L; Jaffee EM; Anders RA; Zheng L
J Vis Exp; 2013 Jan; (71):. PubMed ID: 23328703
[TBL] [Abstract][Full Text] [Related]
20. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.
Okudaira K; Hokari R; Tsuzuki Y; Okada Y; Komoto S; Watanabe C; Kurihara C; Kawaguchi A; Nagao S; Azuma M; Yagita H; Miura S
Int J Oncol; 2009 Oct; 35(4):741-9. PubMed ID: 19724910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
